Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma

被引:11
|
作者
Song, Shaoming [1 ,2 ]
Bai, Mingzhen [1 ]
Li, Xiaofei [2 ]
Gong, Shiyi [2 ,3 ]
Yang, Wenwen [1 ,3 ]
Lei, Caining [2 ,3 ]
Tian, Hongwei [1 ,2 ,4 ]
Si, Moubo [2 ,4 ]
Hao, Xiangyong [2 ,4 ]
Guo, Tiankang [1 ]
机构
[1] Lanzhou Univ, Dept Clin Med, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China
[2] Gansu Prov Hosp, Dept Gen Surg, Lanzhou, Gansu, Peoples R China
[3] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China
[4] Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol, Lanzhou, Gansu, Peoples R China
关键词
Hepatocellular carcinoma; sorafenib; circulating biomarker; survival benefit; liquid biopsy; TO-LYMPHOCYTE RATIO; RESPONSE EVALUATION CRITERIA; ALPHA-FETOPROTEIN RESPONSE; GAMMA-CARBOXY PROTHROMBIN; ENDOTHELIAL GROWTH-FACTOR; PATIENTS RECEIVING SORAFENIB; SOLID TUMORS RECIST; PROGNOSTIC-FACTOR; CHILD-PUGH; PHASE-III;
D O I
10.1080/14737159.2022.2049248
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction Sorafenib is currently the first-line therapeutic regimen for patients with advanced hepatocellular carcinoma (HCC). However, many patients did not experience any benefit and suffered extreme adverse events and heavy economic burden. Thus, the early identification of patients who are most likely to benefit from sorafenib is needed. Areas covered This review focused on the clinical application of circulating biomarkers (including conventional biomarkers, immune biomarkers, genetic biomarkers, and some novel biomarkers) in advanced HCC patients treated with sorafenib. An online search on PubMed, Web of Science, Embase, and Cochrane Library was conducted from the inception to 15 August 2021. Studies investigating the predictive or prognostic value of these biomarkers were included. Expert opinion The distinction of patients who may benefit from sorafenib treatment is of utmost importance. The predictive roles of circulating biomarkers could solve this problem. Many biomarkers can be obtained by liquid biopsy, which is a less or noninvasive approach. The short half-life of sorafenib could reflect the dynamic changes of tumor progression and monitor the treatment response. Circulating biomarkers obtained from liquid biopsy resulted as a promising assessment method in HCC, allowing for better treatment decisions in the near future. Abbreviations Alpha-fetoprotein (AFP); American Association for the Study of Liver Diseases (AASLD); Angiopoietin (Ang); Barcelona Clinic Liver Cancer stage (BCLC); Circulating endothelial progenitor (CEP); Circulating free DNA (cfDNA); Complete response (CR); Des-gamma-carboxy prothrombin (DCP); Endothelium-derived nitric oxide synthase (eNOS); Hepatocellular carcinoma (HCC); Hepatocyte growth factor (HGF); Hepatoma arterial-embolization prognosis score (HAP); High mobility group box 1 (HMgb1); Interferon-gamma (IFN-gamma); Long non-coding RNA (lncRNAs); Micro RNAs (miRNAs); Monocyte-to-lymphocyte ratio (MLR); National Comprehensive Cancer Network (NCCN); Neutrophil-lymphocyte ratio (NLR); Newcastle-Ottawa Scale (NOS); Nitric oxide (NO); Overall survival (OS); Partial response (PR); Platelet-lymphocyte ratio (PLR); Prediction of survival in advanced sorafenib-treated HCC (PROSASH); Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA); Prognostic nutritional index (PNI); Progression-free survival (PFS); Progressive disease (PD); Randomized controlled trials (RCTs); Response Evaluation Criteria in Solid Tumors (RECIST); Single nucleotide polymorphisms (SNPs); Sorafenib advanced HCC prognosis score (SAP); Stable disease (SD); Time to progression (TTP); Transcatheter arterial chemoembolization (TACE); Vascular endothelial growth factor (VEGF).
引用
收藏
页码:361 / 378
页数:18
相关论文
共 50 条
  • [41] What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib?
    Reis, Daniela
    Damiao, Filipe de Sousa
    Simoes, Carolina
    Carvalhana, Sofia
    Goncalves, Afonso
    Marinho, Rui Tato
    Cortez-Pinto, Helena
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E599 - E599
  • [42] Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Reis, Daniela
    Moura, Miguel
    Freitas, Luis Carlos
    Carvalhana, Sofia
    Nogueira, Paulo Jorge
    Gaio, Raquel
    Marinho, Rui Tato
    Cortez-Pinto, Helena
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E114 - E120
  • [43] Predictive Role of the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib
    Tanoglu, Alpaslan
    Karagoz, Ergenekon
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (02) : 1063 - 1063
  • [44] BIOLOGICAL PREDICTIVE FACTORS IN ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH MULTITARGET TYROSINE KINASE INHIBITOR SORAFENIB
    Negri, F.
    Campanini, N.
    Dal Bello, B.
    Rossi, S.
    Tinelli, C.
    Bisagni, G.
    Porta, C.
    Salvagni, S.
    Ardizzoni, A.
    Silini, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 95 - 95
  • [45] Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Reis, Daniela
    Moura, Miguel
    Freitas, Luis Carlos
    Carvalhana, Sofia
    Nogueira, Paulo Jorge
    Gaio, Raquel
    Marinho, Rui Tato
    Cortez-Pinto, Helena
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E114 - E120
  • [46] Early experience of combination treatment of sorafenib and radiotherapy in patients with advanced hepatocellular carcinoma (HCC)
    Seong, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] CIRCULATING MICRORNA IN HEPATOCELLULAR CARCINOMA AS PROGNOSTIC BIOMARKERS
    Pascut, D.
    Krmac, H.
    Mezzina, N.
    Patti, R.
    Licastro, D.
    Dal Monego, S.
    Abazia, C.
    Petraccia, L.
    Masutti, F.
    Croce, S. L.
    Calligaris, R.
    Tiribelli, C.
    [J]. DIGESTIVE AND LIVER DISEASE, 2016, 48 : E23 - E23
  • [48] Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
    Johnson, Philip
    Zhou, Qing
    Dao, Doan Y.
    Lo, Y. M. Dennis
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (10) : 670 - 681
  • [49] Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
    Philip Johnson
    Qing Zhou
    Doan Y Dao
    Y. M. Dennis Lo
    [J]. Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 670 - 681
  • [50] Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
    Hung, Yi-Ping
    Shao, Yu-Yun
    Lee, Jan-Mou
    Hsu, Chiun
    Hsu, Chih-Hung
    Yang, Muh-Hwa
    Chao, Yee
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (02) : 144 - 150